Breaking News Instant updates and real-time market news.

TEVA

Teva

$22.13

0.385 (1.77%)

15:28
01/12/18
01/12
15:28
01/12/18
15:28

Teva debt risk mostly about future refinancing, says Wells Fargo

Wells Fargo analyst David Maris said he thinks it is a mistake to think the only relevant impact to Teva of a debt downgrade is an increase on the rates on its $3.4B of bank debt, saying the "bigger picture" issue is the $20B or more of debt he believes Teva will need to refinance over the next several years at potentially much higher rates. The analyst, who also believes R&D cuts boost near-term numbers but hurt Teva's longer-term prospects and notes that his recent industry interactions "clearly point to the negative pricing environment continuing," keeps an Underperform rating on Teva shares.

TEVA Teva
$22.13

0.385 (1.77%)

01/09/18
MZHO
01/09/18
UPGRADE
MZHO
Buy
Teva upgraded to Buy from Neutral at Mizuho
01/09/18
01/09/18
UPGRADE
Target $23

Buy
Teva upgraded to Buy at Mizuho
As previously reported, Mizuho analyst Irina Koffler upgraded Teva to Buy from Neutral after updating her model for heavier cost cutting, 2017 asset divestitures and slower generic deterioration. The analyst also raised her price target on the shares to $23 from $16.
01/09/18
BMOC
01/09/18
NO CHANGE
Target $26
BMOC
Outperform
Alder Biopharmaceuticals price target raised to $26 from $22 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Alder Biopharmaceuticals (ALDR) to $26 after the release of PROMISE-2 Phase III data in chronic migraine and announcement of settlement with Teva (TEVA) which allows Alder to operate internationally. Luchini says the Phase III update for PROMISE-2 indicates a "competitive profile with potential advantage in chronic setting" for the eptinezumab drug with superior response rates relative to competition. The analyst is keeping his Outperform rating on Alder Biopharmaceuticals.
01/11/18
GSCO
01/11/18
NO CHANGE
Target $25
GSCO
Buy
Teva price target raised to $25 from $20 at Goldman Sachs
Goldman analyst Jami Rubin raised Buy rated Teva's price target to $25 from $20 following the recent investor presentation and management meetings. The analyst believes investor concerns regarding debt issue/downgrade risk combine with the impact from topline portfolio optimization are overstated. Rubin believes there could actually be upside to Copaxone estimates and further FTF opportunities and has increased confidence in the company's deleveraging path.

TODAY'S FREE FLY STORIES

HBI

Hanesbrands

$22.94

-0.26 (-1.12%)

12:50
01/22/18
01/22
12:50
01/22/18
12:50
Options
Hanesbrands puts and calls drawing interest Monday »

Hanesbrands puts and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.47

0.66 (1.47%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Hot Stocks
Intel found root cause for Broadwell and Haswell platform issues »

Intel's Navin Shenoy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

QD

Qudian

$12.50

0.1 (0.81%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.82

0.34 (0.76%)

12:44
01/22/18
01/22
12:44
01/22/18
12:44
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel says made good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

INTC

Intel

$44.82

0.34 (0.76%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel recommends stopping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

BAC

Bank of America

$31.76

0.04 (0.13%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Periodicals
Bank of America eliminates remaining free-checking eBanking accounts, WSJ says »

Bank of America has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MS

Morgan Stanley

$57.02

-0.44 (-0.77%)

12:38
01/22/18
01/22
12:38
01/22/18
12:38
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$45.78

2.43 (5.61%)

12:35
01/22/18
01/22
12:35
01/22/18
12:35
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

12:30
01/22/18
01/22
12:30
01/22/18
12:30
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

12:25
01/22/18
01/22
12:25
01/22/18
12:25
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

OMER

Omeros

$16.70

-0.02 (-0.12%)

12:24
01/22/18
01/22
12:24
01/22/18
12:24
Hot Stocks
Omeros off highs following cautious Twitter mention »

Shares of Omeros are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

, SPX

S&P 500

12:21
01/22/18
01/22
12:21
01/22/18
12:21
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Schumer says deal reached…

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.59

0.12 (0.96%)

12:20
01/22/18
01/22
12:20
01/22/18
12:20
Options
AMD attracts a bullish three-way spread before shares tick higher »

AMD attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BG

Bunge

$80.40

2.84 (3.66%)

, ADM

Archer Daniels

$42.21

1.2505 (3.05%)

12:19
01/22/18
01/22
12:19
01/22/18
12:19
Recommendations
Bunge, Archer Daniels, Glencore analyst commentary  »

Credit Suisse says Archer…

BG

Bunge

$80.40

2.84 (3.66%)

ADM

Archer Daniels

$42.21

1.2505 (3.05%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

$NSD

NASDAQ Market Internals

12:17
01/22/18
01/22
12:17
01/22/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/22/18
01/22
12:16
01/22/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.78

0.16 (0.24%)

12:15
01/22/18
01/22
12:15
01/22/18
12:15
Options
Kellogg put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

12:10
01/22/18
01/22
12:10
01/22/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08
General news
On The Fly: Top stock stories at midday »

Stocks opened mixed, with…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Periodicals
Senators have enough votes to end government shutdown, NBC reports 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, SNY

Sanofi

$43.22

-1.385 (-3.11%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
Hemophilia makers jump after Sanofi acquires peer Bioverativ for huge premium »

Shares of drug companies…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

SNY

Sanofi

$43.22

-1.385 (-3.11%)

PFE

Pfizer

$36.88

-0.06 (-0.16%)

JNJ

Johnson & Johnson

$147.21

-0.15 (-0.10%)

ALNY

Alnylam

$124.83

0.84 (0.68%)

CBIO

Catalyst Biosciences

$19.49

0.86 (4.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

IRIX

IRIDEX

$7.46

-0.11 (-1.45%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
BlueLine Partners reports 8.5% passive stake in IRIDEX »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$37.04

0.155 (0.42%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Options
Opening activity in Olin calls »

Opening activity in Olin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

BK

BNY Mellon

$57.21

0.6 (1.06%)

11:58
01/22/18
01/22
11:58
01/22/18
11:58
Hot Stocks
BNY Mellon to launch FX prime brokerage service »

BNY Mellon announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

, CELG

Celgene

$102.65

0.93 (0.91%)

11:54
01/22/18
01/22
11:54
01/22/18
11:54
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

CELG

Celgene

$102.65

0.93 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.